Atlas Trials

Pierre Fabre Medicament

73 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Pierre Fabre Medicament

RecordFirmDate
An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events) (NCT06690489)Pierre Fabre Medicament2024-11-22
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations (NCT06669117)Pierre Fabre Medicament2024-10-22
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs (NCT06567015)Pierre Fabre Medicament2024-09-17
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment (NCT06500494)Pierre Fabre Medicament2024-09-10
The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study (NCT06688370)Pierre Fabre Medicament2024-03-14
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations (NCT06043817)Pierre Fabre Medicament2023-09-26
Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International Study (NCT07096206)Pierre Fabre Medicament2023-07-19
Study on Structum® in Adult Patients With Osteoarthritis (TRUST) (NCT06623773)Pierre Fabre Medicament2023-06-27
Treatment Patterns of Neratinib in HER2+ EBC in China (NCT05491057)Pierre Fabre Medicament2022-09-30
Prospective Real-World Clinical Investigation on Dexyane Med® in Adults With Chronic Hand Eczema (NCT05545215)Pierre Fabre Medicament2022-09-07
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations (NCT05810740)Pierre Fabre Medicament2022-08-31
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) (NCT05546905)Pierre Fabre Medicament2022-06-23
A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia (NCT07144709)Pierre Fabre Medicament2022-06-22
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (NCT05195632)Pierre Fabre Medicament2022-06-02
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (NCT05270044)Pierre Fabre Medicament2022-05-02
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors (NCT05003622)Pierre Fabre Medicament2021-09-27
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (NCT05004350)Pierre Fabre Medicament2021-09-14
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations (NCT05103891)Pierre Fabre Medicament2021-09-03
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors (NCT04913285)Pierre Fabre Medicament2021-08-04
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (NCT04554914)Pierre Fabre Medicament2021-07-14
Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial (NCT04875026)Pierre Fabre Medicament2021-02-16
A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (NCT04911998)Pierre Fabre Medicament2021-02-02
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma (NCT04759846)Pierre Fabre Medicament2021-01-21
First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid Tumors (NCT04564417)Pierre Fabre Medicament2020-09-08
A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) (NCT04317599)Pierre Fabre Medicament2020-04-12
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (NCT03693170)Pierre Fabre Medicament2019-01-17
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy (NCT03394365)Pierre Fabre Medicament2017-12-29
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors (NCT03316638)Pierre Fabre Medicament2017-11-24

Track Pierre Fabre Medicament automatically

Every clearance here is in the API, with alerts when new ones post.